Ligand Pharmaceuticals Incorporated (LGND)

Last Price: 86.18 (2020-10-27)

Company Description

Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, pain, skin diseases, men's and women's hormone-related diseases, osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases. Ligand's proprietary drug discovery and development programs are based on its leadership position in gene transcription technology, primarily related to intracellular receptors.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $120.28M
Net Income (Most Recent Fiscal Year) $629.30M
PE Ratio (Current Year Earnings Estimate) 29.12
PE Ratio (Trailing 12 Months) 46.21
PEG Ratio (Long Term Growth Estimate) 1.94
Price to Sales Ratio (Trailing 12 Months) 10.82
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 1.96
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) 14.21
Pre-Tax Margin (Trailing 12 Months) -24.01%
Net Margin (Trailing 12 Months) -19.51%
Return on Equity (Trailing 12 Months) 4.41%
Return on Assets (Trailing 12 Months) 2.40%
Current Ratio (Most Recent Fiscal Quarter) 29.51
Quick Ratio (Most Recent Fiscal Quarter) 29.38
Debt to Common Equity (Most Recent Fiscal Quarter) 0.65
Inventory Turnover (Trailing 12 Months) 2.80
Book Value per Share (Most Recent Fiscal Quarter) $43.68
Earnings per Share (Most Recent Fiscal Quarter) $0.65
Earnings per Share (Most Recent Fiscal Year) $2.11
Diluted Earnings per Share (Trailing 12 Months) $-1.38
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 16.08M
Free Float 14.44M
Market Capitalization $1.37B
Average Volume (Last 20 Days) 0.31M
Beta (Past 60 Months) 1.44
Percentage Held By Insiders (Latest Annual Proxy Report) 10.20%
Percentage Held By Institutions (Latest 13F Reports) --
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%